Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration

Journal of Ocular Pharmacology and Therapeutics

Volumn 14, Issue 2, 1998, Pages 153-158

  Howes, John ^a  

^a Pharmos Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DRUG METABOLITE; HYDROCORTISONE; LOTEPREDNOL ETABONATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MASS SPECTROMETRY; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031966882     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1998.14.153     Document Type: Article

References (10)

1. Bodor, N. Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems. Advances Dnig Res. 13:255-331,1984.
2. Bodor, N. Soft drugs: principles and methods for the design of safe drugs. Med. Res. Rev. 4:449-469,1984.
3. Druzgala, P., Wu, W.M., and Bodor, N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr. Eye. Res. 10:933-937,1991.
4. Bartlett, J.D., Horwitz, B., Laibovitz, R., and Howes, J.F. Intraocular pressure response to loteprednol etabonate in known steroid responders. J. Ocul. Pharmacol. 9:157-165,1993.
5. Asbell, P.A., Howes, J., and Loteprednol GPC Study Group II. A double-masked placebocontrolled, evaluation of the efficacy and safety of loteprednol etabonate in the treatment of contact-lens associated giant papillary conjunctivitis. CLAO. J. 23:31-36,1997.
6. Friedlaender, M.H. and Howes, J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am. J. Ophthalmol. 123:455-464,1997.
7. Dell, S.J., Shulman, D.G., Lowry, G.M., and Loteprednol Allergic Conjunctivitis Study Group. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate (LE) in the treatment of seasonal allergic conjunctivitis (SAC). Am. J. Ophthalmol. 123:791-797,1997.
8. Neumann, R. and Howes, J., Loteprednol etabonate: A novel ocular steroid with improved safety profile, In: "Advances in ocular immunology: Proceedings of the 6th international symposium on the immunology and immunopathology of the eye. Bethesda MD", R.B. Nussenblatt et al.., eds., 1994, pp. 245-248.
9. Crapo, L. Cushing's syndrome: a review of diagnostic tests. Metabolism 28:955-977,1979.
10. Stewart, R.H., Smith, J.P., and Rosenthal, A.L. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr. Eye. Res. 3:835-839,1984.